Authors: Ghulam Rasool Bhurgri, Hussain Bux Korijo, Muhammad Ali Qureshi,
Abstract
To evaluate the efficacy and safety of Glibenclamide and Pioglitazone drugs
in type 11 non- insulin dependent diabetes mellitus patients. STUDY DESIGN: study was prospective, randomized study. PLACE AND DURATION: This study was conducted in the department of Pharmacololgy and Therapeutics, Muhammad Medical College Mirpurkhas, in collaboration with Medical Outpatient Department of Civil Hospital Dadu, Sindh PATIENTS, METHOD: Hundred and twenty NIDDM (type-II) diabetic patients were enrolled in the study from the out patient department civil hospital Dadu. All the patients were divided in two groups. RESULTS: In fasting blood sugar, the mean values of glibenclamide group at the start, six months were 150.5 ±22.0, 92.2 ±10.7 respectively, while that of Pioglitazone group were 150.5 ± 22.0, 101.7± 5.4 respectively. Therefore, the mean reduction of two hours postprandial blood glucose from the start till the end of the study (in 6th months) in glibenclamide group was 92.2 ±10.7 and pioglitazone was 101.7± 5.4. . Therefore, the mean reduction of HbA1c in the whole study in glibenclamide group was was6.6 ± .9 and pioglitazone group was7.4 ± .92 .All variables showed significant (P-value >0.05) when we compared between base line and 6 months study time period. In case of safety of drugs in glibenclamide 4.7% and pioglitazone 12% reactions were observed in the study. CONCLUSION: In the light of this study it is obvious that glibenclamide was more effective, tolerable and safer than pioglitazone in a short duration of therapy.
Keywords: Diabetes mellitus, Non-insulin diabetes mellitus, Insulin dependent diabetes mellitus, Glibenclamide, Pioglitazone, Insulin.
